Alkermes PLC Company Profile (NASDAQ:ALKS)

About Alkermes PLC (NASDAQ:ALKS)

Alkermes PLC logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALKS
  • CUSIP: G0176710
  • Web: www.alkermes.com
Capitalization:
  • Market Cap: $7.79808 billion
  • Outstanding Shares: 153,656,000
Average Prices:
  • 50 Day Moving Avg: $51.08
  • 200 Day Moving Avg: $55.51
  • 52 Week Range: $41.93 - $63.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -132.00
  • P/E Growth: -1057.29
Sales & Book Value:
  • Annual Revenue: $804.37 million
  • Price / Sales: 9.83
  • Book Value: $7.82 per share
  • Price / Book: 6.58
Profitability:
  • EBITDA: ($103,300,000.00)
  • Net Margins: -24.33%
  • Return on Equity: -9.12%
  • Return on Assets: -6.40%
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 3.54%
  • Quick Ratio: 3.20%
Misc:
  • Average Volume: 706,558 shs.
  • Beta: 2.2
  • Short Ratio: 8.43
 

Frequently Asked Questions for Alkermes PLC (NASDAQ:ALKS)

What is Alkermes PLC's stock symbol?

Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes PLC's earnings last quarter?

Alkermes PLC (NASDAQ:ALKS) released its quarterly earnings results on Thursday, July, 27th. The company reported $0.01 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.02. The firm earned $218.80 million during the quarter, compared to analysts' expectations of $216.54 million. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The business's revenue was up 12.1% on a year-over-year basis. During the same period last year, the firm posted ($0.01) EPS. View Alkermes PLC's Earnings History.

When will Alkermes PLC make its next earnings announcement?

Alkermes PLC is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Alkermes PLC.

Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?

8 analysts have issued 1-year price objectives for Alkermes PLC's shares. Their forecasts range from $50.00 to $78.00. On average, they expect Alkermes PLC's share price to reach $63.25 in the next twelve months. View Analyst Ratings for Alkermes PLC.

What are analysts saying about Alkermes PLC stock?

Here are some recent quotes from research analysts about Alkermes PLC stock:

  • 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss in the second quarter of 2017 while sales marginally surpassed estimates. Vivitrol and Aristada are anticipated to be primary growth drivers. While, Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. The company also plans to submit a new drug application (NDA) for ALKS 5461 in major depressive disorder and expects to complete the pivotal efficacy of ALKS3831 in schizophrenia. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Moreover, Alkermes’ shares have underperformed the Zacks classified industry year to date." (8/2/2017)
  • 2. Cowen and Company analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)
  • 4. J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)

Who are some of Alkermes PLC's key competitors?

Who are Alkermes PLC's key executives?

Alkermes PLC's management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer
  • Shane M. Cooke, President
  • James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary
  • Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer
  • David Joseph Gaffin, Senior Vice President, Chief Legal Officer

How do I buy Alkermes PLC stock?

Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes PLC's stock price today?

One share of Alkermes PLC stock can currently be purchased for approximately $51.48.


MarketBeat Community Rating for Alkermes PLC (NASDAQ ALKS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  557
MarketBeat's community ratings are surveys of what our community members think about Alkermes PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alkermes PLC (NASDAQ:ALKS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $63.25 (22.86% upside)
Consensus Price Target History for Alkermes PLC (NASDAQ:ALKS)
Price Target History for Alkermes PLC (NASDAQ:ALKS)
Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Barclays PLCDowngradeOverweight -> Equal Weight$66.00 -> $50.00N/AView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$69.00LowView Rating Details
7/1/2017J P Morgan Chase & CoSet Price TargetBuy$78.00LowView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
6/7/2017Credit Suisse GroupReiterated RatingBuy$70.00LowView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00LowView Rating Details
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00MediumView Rating Details
9/27/2016Citigroup Inc.Boost Price TargetNeutral$44.00 -> $53.00N/AView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$57.00 -> $35.00N/AView Rating Details
1/21/2016GuggenheimReiterated RatingHoldN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Alkermes PLC (NASDAQ:ALKS)
Earnings by Quarter for Alkermes PLC (NASDAQ:ALKS)
Earnings History by Quarter for Alkermes PLC (NASDAQ ALKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$0.01N/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.15)($0.15)($0.15)
Q4 20172($0.10)($0.05)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alkermes PLC (NASDAQ:ALKS)
Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 98.51%
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.14View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.00View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.00View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.00View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.00View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.00View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.00View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.00View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.00View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.00View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.00View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.30View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.00View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.00View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.00View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.00View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.00View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.00View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.00View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.56View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.69View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.50View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.00View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.65View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.00View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.00View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.00View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.70View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.00View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.45View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.85View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.00View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.00View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.00View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.00View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.44View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.00View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.92View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.00View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alkermes PLC (NASDAQ:ALKS)
Latest Headlines for Alkermes PLC (NASDAQ:ALKS)
Source:
DateHeadline
businesswire.com logoAlkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7 - Business Wire (press release)
www.businesswire.com - October 16 at 9:37 PM
seekingalpha.com logoAlkermes Stands To Gain From Revenue Increase, Upcoming NDA Submission
seekingalpha.com - October 16 at 4:36 PM
americanbankingnews.com logoHead to Head Survey: Alkermes PLC (ALKS) and The Competition
www.americanbankingnews.com - October 9 at 12:38 PM
finance.yahoo.com logoAlkermes Plc – Value Analysis (NASDAQ:ALKS) : October 6, 2017
finance.yahoo.com - October 6 at 4:03 PM
finance.yahoo.com logoAlkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 5, 2017
finance.yahoo.com - October 5 at 1:16 PM
americanbankingnews.com logo Analysts Expect Alkermes PLC (ALKS) Will Post Quarterly Sales of $234.90 Million
www.americanbankingnews.com - October 5 at 9:46 AM
americanbankingnews.com logoAlkermes PLC (ALKS) Director Paul J. Mitchell Sells 1,500 Shares
www.americanbankingnews.com - October 4 at 8:46 PM
finance.yahoo.com logo[$$] 6 Top Pharma Picks for Q4
finance.yahoo.com - October 4 at 2:38 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 1 at 8:50 AM
zacks.com logoAllergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC
www.zacks.com - September 27 at 8:10 PM
americanbankingnews.com logoAlkermes PLC (ALKS) versus Its Competitors Head-To-Head Survey
www.americanbankingnews.com - September 26 at 2:24 AM
finance.yahoo.com logoAlkermes' ARISTADA Shows Better Results to Treat Schizophrenia
finance.yahoo.com - September 19 at 8:46 PM
nasdaq.com logoAlkermes' ARISTADA Shows Better Results to Treat Schizophrenia - Nasdaq
www.nasdaq.com - September 19 at 3:45 PM
finance.yahoo.com logoAlkermes' ARISTADA Shows Better Results to Treat Schizophrenia
finance.yahoo.com - September 19 at 3:44 PM
streetinsider.com logoAlkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant ...
www.streetinsider.com - September 19 at 2:09 AM
finance.yahoo.com logoPatients Switched to Alkermes’ ARISTADA® Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA®
finance.yahoo.com - September 19 at 2:09 AM
streetinsider.com logoAlkermes plc (ALKS) Says Patients Switched to its ARISTADA ... - StreetInsider.com
www.streetinsider.com - September 18 at 4:07 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Expected to Announce Earnings of $0.01 Per Share
www.americanbankingnews.com - September 14 at 4:14 PM
americanbankingnews.com logoAlkermes PLC (ALKS) CAO Sells $695,800.14 in Stock
www.americanbankingnews.com - September 13 at 7:38 PM
finance.yahoo.com logoAlkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders
finance.yahoo.com - September 6 at 3:41 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Director Sells $76,155.00 in Stock
www.americanbankingnews.com - September 5 at 8:34 PM
businesswire.com logoAlkermes to Present Clinical and Real-World Data at Upcoming 30 th Annual Psych Congress
www.businesswire.com - September 5 at 5:10 PM
nasdaq.com logoAlkermes is Now Oversold (ALKS)
www.nasdaq.com - September 5 at 5:10 PM
finance.yahoo.com logoAlkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress
finance.yahoo.com - September 5 at 5:10 PM
finance.yahoo.com logoAlkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 5:10 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Given a $69.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 26 at 11:02 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: August 23, 2017
seekingalpha.com - August 23 at 3:46 PM
nasdaq.com logoAlkermes Initiates Rolling Submission of Depression Drug - Nasdaq ... - Nasdaq
www.nasdaq.com - August 22 at 9:34 PM
finance.yahoo.com logoAlkermes Initiates Rolling Submission of Depression Drug
finance.yahoo.com - August 22 at 4:31 PM
nasdaq.com logoAlkermes Initiates NDA Submission Of ALKS 5461 For Major Depressive Disorder
www.nasdaq.com - August 21 at 3:54 PM
streetinsider.com logoAlkermes plc (ALKS) Initiates Rolling Submission of NDA for ALKS 5461
www.streetinsider.com - August 21 at 3:54 PM
reuters.com logoBRIEF-Alkermes PLC says ‍initiates rolling submission of ALKS 5461 NDA to U.S. FDA
www.reuters.com - August 21 at 3:54 PM
finance.yahoo.com logoAlkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
finance.yahoo.com - August 21 at 3:54 PM
finance.yahoo.com logoETFs with exposure to Alkermes Plc : August 14, 2017
finance.yahoo.com - August 14 at 9:07 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 11:58 AM
finance.yahoo.com logoIHS Markit Score downgrades Alkermes PLC to 63 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 12 at 2:54 AM
finance.yahoo.com logoIHS Markit Score upgrades Alkermes PLC to 71 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 10 at 5:11 PM
americanbankingnews.com logo$234.90 Million in Sales Expected for Alkermes PLC (NASDAQ:ALKS) This Quarter
www.americanbankingnews.com - August 10 at 8:58 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Alkermes PLC.
finance.yahoo.com - August 10 at 2:00 AM
nasdaq.com logoAlkermes Enters Oversold Territory (ALKS) - Nasdaq
www.nasdaq.com - August 8 at 8:31 PM
americanbankingnews.com logoInsider Selling: Alkermes PLC (ALKS) Director Sells 1,500 Shares of Stock
www.americanbankingnews.com - August 1 at 8:20 PM
finance.yahoo.com logoAlkermes Plc :ALKS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017
finance.yahoo.com - July 31 at 3:49 PM
nasdaq.com logoAlkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat - Nasdaq
www.nasdaq.com - July 30 at 3:31 PM
finance.yahoo.com logoAlkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
finance.yahoo.com - July 29 at 2:35 AM
rttnews.com logoEARNINGS SUMMARY: Details of Alkermes plc Q2 Earnings Report
www.rttnews.com - July 28 at 1:26 AM
nasdaq.com logoALKS Crosses Below Key Moving Average Level
www.nasdaq.com - July 28 at 1:26 AM
seekingalpha.com logoAlkermes' (ALKS) CEO Richard Pops on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - July 28 at 1:26 AM
finance.yahoo.com logoEdited Transcript of ALKS earnings conference call or presentation 27-Jul-17 12:30pm GMT
finance.yahoo.com - July 28 at 1:26 AM
businesswire.com logoAlkermes plc Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - July 27 at 3:19 PM
finance.yahoo.com logoAlkermes plc Reports Second Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 3:19 PM

Social

Chart

Alkermes PLC (ALKS) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.